Renal Cell Carcinoma and Myelodysplastic Syndrome Show Epigenetic Association

Hypermethylation has been documented in some myeloid disorders including myelodysplastic syndrome (MDS) and in renal cell carcinoma (RCC). A group at the Mayo Clinic noticed the epigenetic marking patterns between these vastly different conditions and wondered if there was a connection. The group found that there was a strong association.08/09/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

CONCLUSIONS Matricine induced antiproliferative effects in capan-2 human pancreatic cancer cells through inducing apoptosis, caspase activation, inhibition of cell migration and invasion, and blocking the mTOR/PI3K/AKT signalling pathway. PMID: 31005960 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
CONCLUSIONS In conclusion, in view of the results of this study, it might be suggested that ferruginol might serve as an essential lead molecule for the treatment of thyroid cancer provided further in-depth studies especially studying ferruginol toxicological as well as in vivo studies are needed. PMID: 31005958 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Publication date: Available online 21 April 2019Source: Advances in Biological RegulationAuthor(s): Shaw M. Akula, Saverio Candido, Massimo Libra, Stephen L. Abrams, Linda S. Steelman, Kvin Lertpiriyapong, Giulia Ramazzotti, Stefano Ratti, Matilde Y. Follo, Alberto M. Martelli, Ramiro M. Murata, Pedro L. Rosalen, Bruno Bueno-Silva, Severino Matias de Alencar, Giuseppe Montalto, Melchiorre Cervello, Agnieszka Gizak, Dariusz Rakus, Weifeng Mao, Heng-Liang LinAbstractPancreatic cancer is devastating cancer worldwide with few if any truly effective therapies. Pancreatic cancer has an increasing incidence and may become the sec...
Source: Advances in Biological Regulation - Category: Biology Source Type: research
In this study, we designed pH and redox dual-stage responsive nanocarriers in the different delivery stages for co-delivery phosphorylated curcumin (p-Cur) with doxorubicin (Dox). The MSNs nanocarriers were functionalized via specific cleavable PEGylation and hydrogel coating crosslinked by disulfide bonds: MSNs as core load Dox; p-Cur encapsulated in hydrogel coating. In blood circulation, PEGylation endow the nanocarriers with long time during blood circulation; while in tumor tissue, PEG shells could be cleaved due to the pH-sensitive bond and expose the cationic hydrogel coating to improve cell uptake; while inside tum...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Publication date: Available online 21 April 2019Source: Journal of Organometallic ChemistryAuthor(s): Margaux Elie, Gilbert Umuhire Mahoro, Eric Duverger, Jean-Luc Renaud, Richard Daniellou, Sylvain GaillardAbstractCytotoxicity of cationic (NHC)Cu(I) complexes bearing 2,2′-dipyridylamine (dpa) type ligands has been evaluated toward 4 cancer cell lines, and compared to the one of neutral (NHC)Cu(I) complexes. The high cytotoxicity of these novel cationic (NHC)Cu(I) complexes, combined with the straightforward synthesis, and versatility of dpa type ligands may offer new prospects in cancer research, toward the developm...
Source: Journal of Organometallic Chemistry - Category: Chemistry Source Type: research
ConclusionsWe provided further evidences for implication of miR-100 and mTOR pathway in breast cancer pathogenesis.
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
This study aimed to investigate the prognostic value of systemic inflammatory marker (SIM) in such patients.MethodsSeventy-seven patients who underwent curative surgery for PC with negative TMs were included in this study. Various SIMs for each patient were examined to determine the most reliable one. Using the most superior SIM, the patients were divided into two groups and their characteristics and postoperative results were compared.ResultsThe NLR was superior to other SIMs. Despite no significant intergroup differences were observed between the groups, the overall survival (OS) rate was significantly higher in the low ...
Source: The American Journal of Surgery - Category: Surgery Source Type: research
In this study, we aimed to assess the effects of topical sesame oil in reducing the pain severity of CIP. MATERIALS AND METHODS: This randomized clinical trial was conducted on 60 patients with colorectal cancer afflicted with CIP. Patients received, twice a day for seven consecutive days, a 5-min massage solely (as the control group) or with 10 drops of sesame oil (as the experimental group) within the 10 cm radius of the affected site. The pain severity was evaluated by the visual analog scale on the first, third, fifth, and seventh days of the intervention. RESULTS: Mean changes of the pain severity compared...
Source: Complementary Therapies in Clinical Practice - Category: Complementary Medicine Authors: Tags: Complement Ther Clin Pract Source Type: research
Markus Hartl* and Rainer Schneider Center of Molecular Biosciences (CMBI), Institute of Biochemistry, University of Innsbruck, Innsbruck, Austria The neuronal proteins GAP43 (neuromodulin), MARCKS, and BASP1 are highly expressed in the growth cones of nerve cells where they are involved in signal transmission and cytoskeleton organization. Although their primary structures are unrelated, these signaling proteins share several structural properties like fatty acid modification, and the presence of cationic effector domains. GAP43, MARCKS, and BASP1 bind to cell membrane phospholipids, a process reversibly regulate...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
We report updated results of the primary (PFS) and secondary (overall survival [OS] and toxicity) endpoints.Patients and Methods: Between 4/15/2015-1/27/2016, 27 evaluable pts were treated on 28 day cycles with ELO, 10 mg/kg iv weekly for cycles 1-2, q2weeks for cycles 3-6, then 20 mg/kg once monthly for cycles 7+. Pts enrolled after 1/28/2016 (n=57 pts) have received ELO, 10 mg/kg IV weekly for cycles 1-2, and 20 mg/kg on day 1 from cycle 3 until disease progression (PD). LEN has been dosed at 10 mg/day for cycles 1-3, with a dose increase to 15 mg/day at physician discretion starting with cycle 4, in the absence of non-h...
Source: Blood - Category: Hematology Authors: Tags: 653. Myeloma: Therapy, excluding Transplantation: Poster I Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Myelodysplastic Syndrome | Renal Cell Carcinoma | Urology & Nephrology